Why Ion Beam Applications SA?


▪ IBA is the world leader in proton therapy;
▪ 56% of proton therapy patients have been treated with IBA technology to date;
▪ The company has been a leader in the development of proton therapy for 30 years and has built the largest user          community in the world;
▪ IBA offers the highest availability rates and can install a system in less than 12 months;
▪ Collaborations with major universities and hospitals worldwide;

▪ IBA has built a strong and reliable service team to guarantee the availability of proton therapy technology and              achieve consistent system uptime;

▪ IBA provides support teams, parts and processes to ensure full system operation and maintenance while                      guaranteeing the highest performance standards for its state-of-the-art technology.

Collaboration

Our cancer treatment and research center is located in Wiener Neustadt, about 50 kilometers south of Vienna. It is unique throughout Austria and also one of only six comparable centers worldwide. We operate as an independent outpatient clinic, but are networked with clinics, universities and research institutes - not only throughout Austria, but also internationally.

Our mission is to fight cancer through advanced patient care, clinical trials, applied and basic research, and know-how transfer.

We are constantly striving to improve the therapy method of ion therapy, to increase knowledge about its mode of action and to make the treatment accessible to more people.

A team of more than 250 people is working on this.

Our services include consulting and support already in the project development phase, project management services, support in official licensing procedures, especially in radiation protection, and training of medical and operational staff. We also contribute our expertise in clinical and operational processes and in quality management, and provide support in matters of patient safety and medical-physical acceptance of therapy systems.

During the first years after commissioning, MedAustron will provide logistical, medical-physical and medical support to optimally ensure the transition to routine clinical operation until utilization is achieved within the defined time frame.

The know-how, especially in the area of technological innovations on imaging, beam delivery and treatment planning processes could contribute to the targeted goals. In the medical field, MedAustron offers participation in new studies, joint development of hypofractionated therapy regimens to shorten treatment duration, and establishment of new indications.